Hall Brett Matthew Buys Shares of Immuneering Corporation $IMRX
Key Points
- Hall Brett Matthew bought 6,035 shares of Immuneering Corporation ($IMRX) worth $25,045.25.
- $IMRX last traded around $4.10.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER at Immuneering Corporation ($IMRX), bought 6,035 shares at an average price of $4.15, for a total transaction of $25,045.25. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Immuneering Corporation Stock Down 17.8%
Shares of Immuneering Corporation ($IMRX) traded around $4.10 on Wednesday, down 17.8% for the day.
Immuneering Corporation Earnings
Analysts Set New Price Targets
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Get Immuneering Corporation alerts
New 13F filings, insider trades, and analyst moves on $IMRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.